Cargando…

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1

OBJECTIVE—We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention Trial–Type 1 (DPT-1) participants. RESEARCH DESIGN AND METHODS—The study included oral insulin trial participants and parenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Sosenko, Jay M., Palmer, Jerry P., Rafkin-Mervis, Lisa, Krischer, Jeffrey P., Cuthbertson, David, Matheson, Della, Skyler, Jay S.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571043/
https://www.ncbi.nlm.nih.gov/pubmed/18650369
http://dx.doi.org/10.2337/dc08-0935
_version_ 1782160199351533568
author Sosenko, Jay M.
Palmer, Jerry P.
Rafkin-Mervis, Lisa
Krischer, Jeffrey P.
Cuthbertson, David
Matheson, Della
Skyler, Jay S.
author_facet Sosenko, Jay M.
Palmer, Jerry P.
Rafkin-Mervis, Lisa
Krischer, Jeffrey P.
Cuthbertson, David
Matheson, Della
Skyler, Jay S.
author_sort Sosenko, Jay M.
collection PubMed
description OBJECTIVE—We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention Trial–Type 1 (DPT-1) participants. RESEARCH DESIGN AND METHODS—The study included oral insulin trial participants and parenteral insulin trial control subjects (n = 63) in whom diabetes was diagnosed by a 2-h diabetic oral glucose tolerance test (OGTT) that was confirmed by another diabetic OGTT within 3 months. Differences in glucose and C-peptide levels between the OGTTs were assessed. RESULTS—Glucose levels increased at 90 (P = 0.006) and 120 min (P < 0.001) from the initial diabetic OGTT to the confirmatory diabetic OGTT (mean ± SD interval 5.5 ± 2.8 weeks). Peak C-peptide levels fell substantially between the OGTTs (median change −14.3%, P < 0.001). Among the 55 individuals whose last nondiabetic OGTT was ∼6 months before the initial diabetic OGTT, peak C-peptide levels decreased between these two OGTTs (median change −14.0%, P = 0.052). Among those same individuals the median change in peak C-peptide levels from the last normal OGTT to the confirmatory OGTT (interval 7.5 ± 1.3 months) was −23.8% (P < 0.001). Median rates of change in peak C-peptide levels were 0.00 ng · ml(−1) · month(−1) (P = 0.468, n = 36) from ∼12 to 6 months before diagnosis, −0.10 ng · ml(−1) · month(−1) (P = 0.059, n = 55) from 6 months before diagnosis to diagnosis, and −0.43 ng · ml(−1) · month(−1) (P = 0.002, n = 63) from the initial diabetic OGTT to the confirmatory diabetic OGTT. CONCLUSIONS—It seems that postchallenge C-peptide levels begin to decrease appreciably in the 6 months before diagnosis and decrease even more rapidly within 3 months after diagnosis.
format Text
id pubmed-2571043
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-25710432009-11-01 Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 Sosenko, Jay M. Palmer, Jerry P. Rafkin-Mervis, Lisa Krischer, Jeffrey P. Cuthbertson, David Matheson, Della Skyler, Jay S. Diabetes Care Pathophysiology/Complications OBJECTIVE—We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention Trial–Type 1 (DPT-1) participants. RESEARCH DESIGN AND METHODS—The study included oral insulin trial participants and parenteral insulin trial control subjects (n = 63) in whom diabetes was diagnosed by a 2-h diabetic oral glucose tolerance test (OGTT) that was confirmed by another diabetic OGTT within 3 months. Differences in glucose and C-peptide levels between the OGTTs were assessed. RESULTS—Glucose levels increased at 90 (P = 0.006) and 120 min (P < 0.001) from the initial diabetic OGTT to the confirmatory diabetic OGTT (mean ± SD interval 5.5 ± 2.8 weeks). Peak C-peptide levels fell substantially between the OGTTs (median change −14.3%, P < 0.001). Among the 55 individuals whose last nondiabetic OGTT was ∼6 months before the initial diabetic OGTT, peak C-peptide levels decreased between these two OGTTs (median change −14.0%, P = 0.052). Among those same individuals the median change in peak C-peptide levels from the last normal OGTT to the confirmatory OGTT (interval 7.5 ± 1.3 months) was −23.8% (P < 0.001). Median rates of change in peak C-peptide levels were 0.00 ng · ml(−1) · month(−1) (P = 0.468, n = 36) from ∼12 to 6 months before diagnosis, −0.10 ng · ml(−1) · month(−1) (P = 0.059, n = 55) from 6 months before diagnosis to diagnosis, and −0.43 ng · ml(−1) · month(−1) (P = 0.002, n = 63) from the initial diabetic OGTT to the confirmatory diabetic OGTT. CONCLUSIONS—It seems that postchallenge C-peptide levels begin to decrease appreciably in the 6 months before diagnosis and decrease even more rapidly within 3 months after diagnosis. American Diabetes Association 2008-11 /pmc/articles/PMC2571043/ /pubmed/18650369 http://dx.doi.org/10.2337/dc08-0935 Text en Copyright © 2008, American Diabetes Association https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Pathophysiology/Complications
Sosenko, Jay M.
Palmer, Jerry P.
Rafkin-Mervis, Lisa
Krischer, Jeffrey P.
Cuthbertson, David
Matheson, Della
Skyler, Jay S.
Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
title Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
title_full Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
title_fullStr Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
title_full_unstemmed Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
title_short Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
title_sort glucose and c-peptide changes in the perionset period of type 1 diabetes in the diabetes prevention trial–type 1
topic Pathophysiology/Complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571043/
https://www.ncbi.nlm.nih.gov/pubmed/18650369
http://dx.doi.org/10.2337/dc08-0935
work_keys_str_mv AT sosenkojaym glucoseandcpeptidechangesintheperionsetperiodoftype1diabetesinthediabetespreventiontrialtype1
AT palmerjerryp glucoseandcpeptidechangesintheperionsetperiodoftype1diabetesinthediabetespreventiontrialtype1
AT rafkinmervislisa glucoseandcpeptidechangesintheperionsetperiodoftype1diabetesinthediabetespreventiontrialtype1
AT krischerjeffreyp glucoseandcpeptidechangesintheperionsetperiodoftype1diabetesinthediabetespreventiontrialtype1
AT cuthbertsondavid glucoseandcpeptidechangesintheperionsetperiodoftype1diabetesinthediabetespreventiontrialtype1
AT mathesondella glucoseandcpeptidechangesintheperionsetperiodoftype1diabetesinthediabetespreventiontrialtype1
AT skylerjays glucoseandcpeptidechangesintheperionsetperiodoftype1diabetesinthediabetespreventiontrialtype1